Shortlist Indian API suppliers that combine an NAI inspection, an active DMF, and visible trade volume on the molecule. The qualifiable shortlist.
Five Indian suppliers pass the three-criterion filter for linagliptin: most recent FDA inspection classed NAI, at least one active Type II DMF on the molecule, and at least one observable 2025 export shipment. Alembic Pharmaceuticals leads on filing recency (March 2026), Biocon on multi-criterion strength, and MSN Pharmachem on dossier count.
| # | Supplier | Plant + class | Active DMFs | 2025 trade | Filter result |
|---|---|---|---|---|---|
| 1 | Alembic Pharmaceuticals | IN · Vadodara | 2 DMFs | Mar 2026 · active trade | NAI |
| 2 | Biocon | IN · Bengaluru | 2 DMFs | Mar 2025 · active trade | NAI |
| 3 | MSN Pharmachem | IN · Hyderabad | 2 DMFs | May 2025 · active trade | VAI |
| 4 | Honour Lab | IN · Visakhapatnam | 2 DMFs | Jan 2015 · active trade | VAI |
| 5 | Morepen Laboratories | IN · Solan | 2 DMFs | Aug 2021 · active trade | VAI |
Type the INN. The AI agent pulls every Indian-incorporated DMF holder for that molecule from the FDA register.
Most recent inspection class NAI (or NAI plus VAI improving), at least one active Type II DMF, non-zero 2025 exports. Suppliers that fail any leg drop out.
Citation-anchored brief with the qualifying cohort, sub-scores per leg, and a chip showing the recent inspection date.
NAI is the highest FDA inspection outcome. Filtering on it removes plants under enforcement risk before the buyer ever sees them.
An Indian holder with NAI and an active DMF but zero exports may be capable but is not on the qualifiable shortlist for an immediate RFQ.
Recent first-filed dates indicate active commercial intent on the molecule. A holder filing in 2026 is a different signal than one with a 2014 vintage filing.
Inspection feed, DMF register, and trade aggregates refresh weekly. A supplier moving from VAI to NAI surfaces on the next refresh.
A real chat thread in PharmaDB. Type a question, the AI agent runs the tools, the answer lands as a saveable note.
pharmagraph_query Twenty molecules · count of Indian suppliers passing NAI + active DMF + 2025 trade filter.
The low-risk Indian shortlist is the hard-filtered cohort of qualifiable suppliers. PharmaDB joins inspection class, active DMF coverage, and trade aggregates at the supplier entity so the three-leg filter is one query, not three. The view rests on api_docs, inspections, and company_trade_exports_by_molecule. Refresh cadence is weekly.
NAI (No Action Indicated) is the highest FDA inspection outcome. It means the inspector found no objectionable conditions warranting administrative action. Filtering on NAI removes both VAI plants (objectionable conditions but no action) and OAI plants (active enforcement) from the immediate shortlist.
Yes by default, but the filter is configurable. Many VAI plants are eminently qualifiable with strong CAPA evidence at qualification. Buyers can switch the filter to 'NAI or VAI improving' to widen the cohort while still excluding deteriorating or OAI plants.
Country of incorporation of the supplier's legal entity and country of the manufacturing plant must both be India. A US-incorporated agent for an Indian manufacturer would still surface, with India as the plant country.
The three-leg filter is strict. Many capable Indian suppliers carry VAI or have not shipped on the molecule in the latest trade year. The companion analysis 'Long-tail tier-2 Indian API houses' surfaces qualifiable suppliers that miss one leg.
The shortlist is a hard-filter view. The supplier scorecard is a soft-rank view across all candidates. A buyer typically uses the shortlist to derive a focused RFQ pool and the scorecard to back-fill candidates if the pool is thin.
Weekly. Inspection feed, DMF register, and trade aggregates all refresh weekly. The three-leg filter reruns on every refresh; the catalog row carries an as-of timestamp.
Bring the molecule, the lane, or the supplier you're sourcing this week. The AI agent runs it on PharmaDB in 30 minutes. You keep the brief.